List of Excipients in Branded Drug VALSARTAN

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	VALSARTAN	valsartan	0781-5607	CELLULOSE, MICROCRYSTALLINE
Sandoz Inc	VALSARTAN	valsartan	0781-5607	CROSPOVIDONE
Sandoz Inc	VALSARTAN	valsartan	0781-5607	FERRIC OXIDE YELLOW

Generic Drugs Containing VALSARTAN

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	valsartan	0378-5807	CROSPOVIDONE
Mylan Pharmaceuticals Inc	valsartan	0378-5807	FERRIC OXIDE RED
Mylan Pharmaceuticals Inc	valsartan	0378-5807	FERRIC OXIDE YELLOW

What are the Most Frequently-Used Excipients in VALSARTAN?

# Of NDCs	Excipient
8	ANHYDROUS LACTOSE
86	CELLULOSE, MICROCRYSTALLINE
1	CI 77492

Valsartan Excipient Strategy, Formulation Opportunities, and Commercial Outlook

Last updated: October 14, 2026

Valsartan is a mature angiotensin II receptor blocker with extensive generic competition and limited conventional patent protection. The strongest commercial opportunities are in differentiated oral delivery: pediatric liquids, taste-masked formulations, orally disintegrating tablets, flexible-dose products, fixed-dose combinations, and formulations with tighter control of dissolution and impurity risk. Excipient selection must preserve valsartan’s low and variable aqueous solubility while meeting regulatory expectations for nitrosamine control, content uniformity, stability, and bioequivalence.

What is the commercial status of valsartan?

Valsartan is an orally active angiotensin II receptor type 1 antagonist used for hypertension, heart failure, and post-myocardial-infarction management. In the United States, valsartan is marketed as a generic tablet and in combination products, including valsartan/hydrochlorothiazide and sacubitril/valsartan. The originator product Diovan was developed by Novartis. The active pharmaceutical ingredient is chemically defined, non-biologic, and eligible for an abbreviated new drug application pathway when a generic product meets FDA requirements.

Attribute	Valsartan
Drug class	Angiotensin II receptor blocker
Primary indications	Hypertension, heart failure, post-myocardial infarction
Common dosage forms	Immediate-release tablets; combination tablets; oral suspension or liquid presentations in selected markets
Typical strengths	40 mg, 80 mg, 160 mg, 320 mg
Biopharmaceutic issue	Low aqueous solubility and variable absorption
Regulatory pathway	ANDA for standard generics; NDA or 505(b)(2) for differentiated delivery systems
Originator	Novartis, Diovan
Patent position	Core compound and original product protection have expired in the United States
Current market structure	Predominantly generic and price competitive

Valsartan has no biosimilar pathway because it is a small-molecule drug. Competitive entry is therefore based on generic approval, manufacturing cost, supply reliability, dosage-form differentiation, and contracting rather than biologic interchangeability.

What patents protect valsartan?

The core valsartan composition-of-matter patent has expired. The original U.S. patent commonly associated with valsartan is U.S. Patent No. 5,399,578, assigned to Ciba-Geigy, later part of Novartis. The patent issued in 1995 and had a term extending into 2012 after applicable patent-term adjustments and extensions. FDA patent and exclusivity records identify the Diovan franchise as an early generic-entry market rather than an active composition-of-matter exclusivity market [1, 2].

How strong is the current valsartan patent estate?

The current estate is weak for ordinary valsartan tablets because:

• The active ingredient is off patent.
• Core immediate-release tablet technology is widely practiced.
• Multiple generic manufacturers have established products.
• A formulation patent would need to provide a meaningful technical distinction and survive obviousness scrutiny.
• Method-of-use claims face limited commercial value where the indications are established and generic substitution is widespread.

Potentially relevant protection can still arise from:

• A novel pediatric liquid.
• A specific taste-masking system.
• A stable amorphous or nanocrystalline form.
• A co-crystal or salt with improved performance.
• A combination product.
• A manufacturing process that produces a distinct impurity profile.
• A device-enabled or modified-release presentation.

These rights would generally protect a product configuration rather than valsartan itself.

When does valsartan lose exclusivity?

Valsartan lost U.S. small-molecule exclusivity years ago. The commercial loss of exclusivity occurred when generic valsartan products entered the market after expiration of the originator’s core patent and regulatory exclusivity position. Current products compete primarily on price, supply, quality, and customer access.

Protection category	Status
Valsartan compound patent	Expired
Original Diovan market exclusivity	Expired
Standard immediate-release tablet protection	No broad active exclusivity identified
Pediatric exclusivity	Historical and expired where applicable
Generic competition	Established
Biosimilar exposure	Not applicable
Formulation-specific opportunities	Possible through new patents and regulatory filings

The commercial implication is that a new excipient strategy must create a measurable product advantage. Replacing one conventional filler with another is unlikely to support meaningful pricing or durable market share.

What excipients are used in valsartan tablets?

Commercial valsartan tablets use conventional direct-compression or wet-granulation excipients. Public product labels identify combinations that can include microcrystalline cellulose, crospovidone, povidone, colloidal silicon dioxide, magnesium stearate, talc, polyethylene glycol, hypromellose, titanium dioxide, and iron oxides [3, 4].

What does each excipient contribute?

Excipient class	Typical function in valsartan tablets	Commercial and technical considerations
Microcrystalline cellulose	Diluent and compression aid	Supports tablet hardness and manufacturability
Crospovidone	Superdisintegrant	Promotes rapid breakup without substantial gelling
Povidone	Binder	Controls granule strength and tablet friability
Colloidal silicon dioxide	Glidant and moisture-control aid	Can improve powder flow; excessive levels may affect compaction
Magnesium stearate	Lubricant	Over-lubrication can slow wetting and dissolution
Talc	Glidant or anti-adherent	May affect dissolution and powder handling
Hypromellose	Film former or matrix former	Useful for coating; higher levels can alter release
Polyethylene glycol	Plasticizer in film coating	Supports coating flexibility
Titanium dioxide and iron oxides	Opacifier and colorant	Important for product identification and light protection

Valsartan’s formulation challenge is less about tablet disintegration than about achieving reproducible dissolution and absorption from a drug substance with limited water solubility. Excipient selection must therefore be linked to particle size, polymorphic form, wetting, granulation method, lubricant exposure, and dissolution media.

What excipient strategy improves valsartan bioavailability?

A practical strategy begins with API characterization rather than excipient screening alone. Key variables include particle-size distribution, specific surface area, crystallinity, polymorphic form, bulk density, flow, hygroscopicity, and degradation profile.

Wetting and dissolution strategy

Surfactants or wetting agents may improve contact between valsartan particles and gastrointestinal fluid. Candidates can include sodium lauryl sulfate, poloxamers, polysorbates, and certain low-level nonionic surfactants. The selection must balance:

• Dissolution improvement.
• Chemical stability.
• Taste and gastrointestinal tolerability.
• Compatibility with the API and packaging.
• Regulatory acceptability at the proposed level.

Superdisintegrants such as crospovidone, croscarmellose sodium, and sodium starch glycolate can improve tablet breakup. They do not necessarily solve the intrinsic solubility problem. Their performance depends on compression force, lubricant concentration, granulation, and tablet porosity.

Amorphous and particle-engineering strategy

Amorphous solid dispersions, spray-dried dispersions, co-precipitates, nanocrystals, and co-crystals could create stronger differentiation than a conventional excipient substitution. Suitable polymer systems may include hypromellose acetate succinate, copovidone, povidone, and hydroxypropyl cellulose.

These systems carry development risks:

• Physical recrystallization.
• Moisture sensitivity.
• Polymer-related dissolution changes during storage.
• More complex scale-up.
• Higher manufacturing cost.
• Greater need for solid-state characterization.

A technically successful system should demonstrate a sustained advantage after accelerated stability testing, not only an initial dissolution increase.

What formulations are protected by valsartan excipient patents?

No single excipient is likely to provide meaningful exclusivity by itself. Patent value generally comes from a defined combination of:

• Valsartan particle properties.
• A specified polymer or surfactant ratio.
• A manufacturing process.
• Dissolution performance.
• Stability limits.
• Bioavailability or pharmacokinetic outcomes.
• A specific dosage form or patient population.

A formulation claim that broadly covers valsartan with a common disintegrant or binder would face substantial validity risk. A narrower claim directed to a stable amorphous dispersion, a defined particle-size distribution, a novel co-crystal, or a pediatric taste-masked liquid may offer stronger differentiation if supported by comparative data.

What dosage forms offer the best excipient opportunity?

Pediatric oral liquid

A pediatric product could address patients who cannot swallow tablets. The principal formulation problems are:

• Valsartan’s low aqueous solubility.
• Bitter taste.
• Physical sedimentation.
• Dose uniformity after shaking.
• Preservative compatibility.
• Chemical stability in water-containing systems.

A suspension may be more practical than a true solution. Suspending agents can include xanthan gum, microcrystalline cellulose/carboxymethylcellulose systems, or other pharmaceutically accepted rheology modifiers. Taste masking may require sweeteners, flavors, ion-exchange resins, polymer coating, or a multiparticulate approach.

The FDA has approved valsartan-containing oral suspension products in defined clinical contexts, including pediatric heart failure presentations associated with sacubitril/valsartan. Product developers must distinguish a new standalone valsartan liquid from an already established combination-product presentation [5].

Orally disintegrating tablet

An orally disintegrating tablet could target dysphagia, geriatric patients, and adherence-sensitive populations. The formulation must maintain rapid disintegration without generating unacceptable bitterness. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and flavor systems are common platform components, but the commercial value depends on demonstrated patient benefit and reliable taste masking.

Fixed-dose combination

Valsartan combinations with hydrochlorothiazide, amlodipine, or sacubitril have greater commercial relevance than a reformulated valsartan monoproduct. Combination products can reduce pill burden and support chronic-care adherence. They also create more difficult compatibility and dissolution requirements because each active ingredient can respond differently to pH, moisture, compression, and excipient composition.

Modified-release formulation

A modified-release valsartan product could create new intellectual property, but the clinical rationale is less obvious because valsartan is already administered once or twice daily depending on indication and product. Development would require evidence that altered exposure improves efficacy, tolerability, adherence, or a defined patient outcome.

What FDA regulatory status applies to a new valsartan formulation?

A conventional tablet that is pharmaceutically equivalent and bioequivalent to an approved reference product can generally proceed through the ANDA route. A product with a materially different dosage form, strength, route, indication, or clinical profile may require an NDA or 505(b)(2) application.

Product concept	Likely U.S. pathway
Conventional generic tablet	ANDA
Generic valsartan/hydrochlorothiazide tablet	ANDA against the relevant reference product
New pediatric suspension	NDA or 505(b)(2), depending on reference and formulation
New orally disintegrating tablet	Potentially ANDA if it meets reference-product requirements; otherwise 505(b)(2)
Amorphous dispersion with new clinical claims	505(b)(2) or NDA
New fixed-dose combination	NDA or 505(b)(2), depending on active ingredients and reference products

FDA review will focus on pharmaceutical equivalence, bioequivalence, dissolution, impurities, stability, manufacturing controls, and labeling. For liquids and suspensions, dose uniformity, redispersibility, preservative effectiveness, microbial limits, and in-use stability are central.

What nitrosamine risks affect valsartan manufacturing?

Valsartan was among the drugs affected by the 2018 discovery of nitrosamine impurities, particularly N-nitrosodimethylamine and N-nitrosodiethylamine, in certain active pharmaceutical ingredient supply chains. FDA linked the issue to manufacturing-process changes and the use of solvents or reagents that created conditions for impurity formation [6].

The primary control point is API manufacturing, not the tablet excipient system. Excipient strategy still matters because developers must assess:

• Nitrite levels in excipients.
• Amine-containing excipients.
• Moisture and thermal exposure.
• Packaging interactions.
• Nitrosamine formation during storage.
• Supplier variability and change control.

A low-nitrite excipient supply chain, validated raw-material specifications, and risk-based analytical testing can support a stronger regulatory package. Developers should not assume that an excipient is low risk solely because it has a long history of use in other products.

Which companies are challenging the valsartan market?

The market includes multinational generic manufacturers, regional pharmaceutical companies, contract manufacturers, and vertically integrated API suppliers. Because the core product is off patent, competition is primarily operational rather than litigation-driven.

Important competitive dimensions include:

• API source qualification.
• Cost of goods.
• FDA inspection history.
• Drug-shortage resilience.
• Tablet capacity.
• Combination-product portfolio.
• Retail and institutional contracting.
• Ability to supply multiple strengths.
• Control of nitrosamine impurities.

A differentiated formulation is more likely to succeed through a targeted channel, such as pediatric care, hospital discharge, specialty pharmacy, or adherence programs, than through an undifferentiated retail tablet launch.

What patent litigation and Paragraph IV risks affect valsartan?

Paragraph IV litigation risk is limited for the original valsartan compound because the principal patent estate has expired. New litigation risk would arise from later patents covering:

• A novel solid form.
• A specific formulation.
• A combination product.
• A manufacturing process.
• A method of treating a narrowly defined population.

For a new formulation, patent strategy should separate claims into product, process, and use categories. Process claims may be difficult to enforce against an imported API or finished product if the process cannot be detected in the final dosage form. Product-by-process claims are generally weaker than claims directed to measurable structural or performance characteristics.

Settlement agreements are more relevant to later combination or formulation patents than to ordinary valsartan tablets. No active settlement framework is required to explain the commercial availability of generic valsartan.

How does valsartan compare with other ARBs?

Drug	Generic status	Formulation opportunity	Commercial differentiation
Valsartan	Mature generic	Pediatric liquid, combinations, taste masking, solid-state systems	Strong clinical familiarity; intense price competition
Losartan	Mature generic	Oral liquids and combination products	Very broad generic base; low pricing
Irbesartan	Mature generic	Combination and dissolution optimization	Similar chronic-use market
Candesartan	Mature generic	Prodrug-related formulation and pediatric applications	More complex API and formulation considerations
Olmesartan	Mature generic	Combination products and modified delivery	Distinct safety-labeling considerations
Telmisartan	Mature generic	Solubility and solid-dispersion systems	Formulation complexity can support technical differentiation

Valsartan remains attractive for formulation development because it has large clinical use, established dosing, and known solubility challenges. It is less attractive for a simple tablet launch because generic competition is extensive.

What revenue exposure and commercial opportunities exist?

Revenue potential depends on product positioning. A conventional valsartan tablet is a low-margin volume opportunity. A differentiated product can support higher margins if it addresses a defined unmet need and obtains a defensible regulatory or patent position.

Higher-potential opportunities

1. Pediatric suspension with validated dose uniformity and taste masking.
2. Hospital-friendly unit-dose liquid or dispersible formulation.
3. Fixed-dose combination with improved adherence.
4. Low-nitrosamine, supply-secure product supported by qualified API and excipient suppliers.
5. Orally disintegrating or sprinkle formulation for dysphagia.
6. Stable amorphous or nanocrystal formulation with demonstrated exposure improvement.
7. Regional licensing of differentiated dosage forms where generic liquid competition is limited.

Lower-potential opportunities

• Changing only the tablet color.
• Replacing one standard filler with another.
• Minor changes to coating composition.
• A conventional tablet with no supply, quality, or adherence advantage.
• Broad formulation claims unsupported by comparative performance data.

Key Takeaways

• Valsartan’s core patent and original exclusivity position have expired.
• Standard immediate-release tablets are difficult to differentiate and face intense generic price competition.
• The strongest excipient opportunities involve solubility enhancement, taste masking, suspension stability, and rapid disintegration.
• Pediatric liquids and fixed-dose combinations offer the clearest commercial rationale.
• Nitrosamine control is primarily an API-manufacturing issue, but excipient nitrite content and storage conditions require assessment.
• New formulation patents should focus on measurable product characteristics, defined compositions, manufacturing controls, or clinically relevant use cases.
• A differentiated valsartan product would likely require an NDA or 505(b)(2) strategy unless it qualifies as an ANDA-equivalent dosage form.
• No biosimilar pathway applies because valsartan is a small molecule.
• Commercial success depends more on formulation utility, supply reliability, and channel strategy than on protection for the active ingredient.

FAQs About Valsartan Excipient and Formulation Strategy

Can valsartan be formulated as a true aqueous solution?

Valsartan has limited aqueous solubility, so a suspension or solubilized system is generally more practical than a simple water-based solution. A true solution requires pH adjustment, cosolvents, complexation, or another solubility-enhancement mechanism that remains stable and acceptable for oral use.

Which excipient is best for valsartan dissolution?

No single excipient is universally best. Crospovidone, croscarmellose sodium, wetting agents, particle engineering, and polymeric dispersion systems can each improve performance. The optimal system depends on API particle properties, compression conditions, dissolution targets, and stability.

Does valsartan have active Orange Book patents?

The original valsartan compound protection associated with Diovan has expired. Any current Orange Book patents would need to be evaluated product by product, particularly for combination products or later formulations. Standard valsartan tablets do not depend on active compound-patent exclusivity.

Is a valsartan pediatric product commercially attractive?

Yes, if the product provides reliable dosing, acceptable taste, storage stability, and convenient administration. Pediatric demand is more specialized than the adult tablet market, but a well-designed liquid or dispersible product can avoid direct price competition with conventional tablets.

Can a valsartan excipient patent block generic entry?

It can block a specific formulation if valid, enforceable, and relevant to the commercial product. It cannot generally block all valsartan products unless the patent claims reach the entire market, which would be difficult for a mature active ingredient with numerous established formulations.

References

1. U.S. Patent and Trademark Office. (1995). U.S. Patent No. 5,399,578, "N-(1-Oxo-pentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine."
2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
3. U.S. Food and Drug Administration. (n.d.). Diovan prescribing information. Novartis Pharmaceuticals Corporation.
4. DailyMed. (n.d.). Valsartan tablet prescribing information and inactive ingredient listings. National Library of Medicine.
5. U.S. Food and Drug Administration. (2021). Entresto prescribing information. Novartis Pharmaceuticals Corporation.
6. U.S. Food and Drug Administration. (2024). Nitrosamine impurities in medications: Guidance and regulatory updates.